Developments in the inhibition of gastric acid secretion

Abstract

Understanding the physiology of gastric acid secretion and the pathophysiology of acidrelated diseases (e.g. gastrooesophageal reflux and peptic ulcer) has led to the development of numerous ways to decrease acid exposure. Pharmacologically one can try to neutralize secreted acid by antacids, prevent stimulation of the parietal cell, improve mucosal defences and block the functioning of the proton pump. Proton pump inhibitors (PPIs) inhibit the final step of acid secretion, and are currently the most potent acid inhibitors. Major therapeutic improvement within the PPI class appears unlikely, as agents in this class share similar chemistry, mode of action, and pharmacokinetic profiles. New approaches that block acid secretion are now being developed. Gastrin (CCK 2 ) receptor antagonists and potassium-competitive acid blockers (P-CABs) are in clinical development.Keywords Gastrin (CCK 2 ) receptor antagonist, gastrooesophageal reflux disease, H + ,K + -ATPase, H 2 -blocker, histamine (H 2 ) receptor antagonist, peptic ulcer, potassium-competitive acid blocker (P-CAB), proton pump inhibitor. Eur J Clin Invest 2005; 35 (8): 469-475

Systematic expression profiling of the gastric H+/K+ATPase in human tissue

“…This was the class of P-CABs with a different, reversible inhibition mechanism [21,22]. Some of these also accumulate in acidic compartments because of their pK a but there is no pH-dependent activation and no covalent linking mechanism.…”

Does the Histamine H₄ Receptor Have a Pro- or Anti-Inflammatory Role in Murine Bronchial Asthma?

“…Furthermore, histamine regulates gastric acid secretion and the recruitment of immune-competent cells to the site of infection [2] . These and other effects are mediated by histaminespecific receptors expressed on the respective target cells.…”

Effect of perioperative proton pump inhibitors on the incidence of pharyngocutaneous fistula after total laryngectomy: A prospective randomized controlled trial

“…They act by irreversibly binding to and inhibiting the H + ,K + ‐ATPase enzyme of the gastric parietal cell. PPIs may be administered intravenously, orally, or via a nasogastric feeding tube and have been proven to abolish acid secretion within 24 hours . This rapid efficacy and potential for once‐daily dosage has been found to increase compliance .…”